540 likes | 1.89k Views
Myasthenia Gravis. Autoimmune disorderAntibodies directed against acetylcholine receptor (AChR)Best understood clinical disorder of neuroreceptor function.Clinically characterised by weakness and fatigability on sustained effortIntensive care required due to severe involvement of bulbar and respiratory muscles.
E N D
1. Myasthenia GravisGuillain-Barre Syndrome
ICU teaching
April 27th
3. incidence 1 in 20 000
No racial or geographical prediliction
Any age although rare in <2yrs
Peaks incidence in young females
Females x2 males
Gender preference diminishes with increasing age
Smaller second peak in elderly males
4. Pathophysiology IgG AB interact with the postsynaptic AChR at the nicotinic neuromuscular junction(NMJ).
This reduces the number of functional receptors by blocking Ach attachment, by increasing the degradation of receptors and by complement induced damage to the NMJ
MG pts have a reduced AChR density and have 30% the normal number of AChR
This reduces the safety margin at the NMJ
5. The reduced AChR density leads to decreased amplitude in AP in the post synaptic region leading to failure in initiation in muscle fibre contraction.
When it occurs at many NMJs manifests as weakness of voluntary muscle-cardinal feature
6. Aetiolgy Antibody mediated, origin uncertain
Thymus gland possible generator
Gland abnormal in 75% of patients with MG( hyperplasia and thymoma)
B and T lymphocytes become sensitised to AChR found in myoid cells in the gland
Reason for breakdown in normal immune tolerance uncertain
7. Clinical features Voluntary muscle weakness cardinal feature, with fatigability, relieved with rest
15% pts have disease confined to the eyes
85% generalised ocular, facial, bulbar, limb
Respiratory muscles affected mildly however in myasthenic crisis resp failure requiring support may be required
Symptoms of diplopia, ptosis, dysarthria, regurgitation,dysphagia are all common.
8. Diagnosis and Ix History and examination
EMG
Recording of compound muscle action potentials(CMAP)
Following repetitive stimulation of motor nerve
In MG this leads to reduction in CMAP (>10%)
9. All EMG abnormalities are not specific for MG
Detection of anti-AChR antibodies
In 80-85% cases and are pathognomonic
The Tensilon test-
up to 10mg edrophonium is administered IV is standard test.
Mg pts show marked improvement after 30sec and lasts 5min
10. Management Anticholinesterase drugs potentiate the Ach at receptor sites, Pyridostigmine most common up to 60mg QID. Effects diminish over months
Thymectomy best results and advocated early in all patients regardless of severity or presence of thymoma. Earlier remission, lower mortality, greater delay in recurrences.
11. Management continued Immunosuppression - corticosteroids mainstay
effective in 70%
best results when used high dose and reduced
average of 4months with some indefinitely
Azothiprine and methotrexate effective adjuncts, 80% helped, few remission
12. Mx continued Plasma exchange effective in achieving short term remission, for preoperative thymectomy, in myasthenic crisis or respiratory failure. Reduction in level of antibodies correlates with the improvement in muscle power. Improvement seen within days and is short lived.five exchanges 3-4litres each over 2 weeks
Iv IG similar effects as plasma exchange , 400mg/kg/day for 5days. Some pts get long term benefit. No effect on ab numbers and mechanism of action unknown.
13. Complications of all treatments Sepsis and infections related to IV catheters and immunosuppression
Renal failure from IgG and Cyclosporin
All the complications of long term steroid use
14. Myasthenic and cholinergic crisis Known MG pts may have life threatening acute deteriorations
Following infections, pregnancy and administration of some drugs
Most resolve over several weeks some last months
Incidence of M.crisis increases with age
15. Management of the crisis Risk of pulmonary aspiration due to bulbar muscle involvement, bacterial pneumonia due to stasis, acute resp failure and cardiorespiratory arrest.
Resusitation as for any patient
Followed by edrophonium, this will indicate whether patient will respond to increasing dose of anticholinergic drug.
16. If edrophonium worsens condition patient suffering cholinergic crisis which is due to over admin of anticholinesterase drugs( cramps, brady,salivation,diarrhoea)
Improvement seen if anticholinesterase drugs reduced, withdrawn and restarted
17. ICU management Frequent estimations of VC and inspiratory force
Consideration of mechanical ventilation given to those with severe bulbar and respiratory muscle involvement
Deterioration of ABGs often late sign
Good ICU care, maintaining K, Ca Mg levels normal. Physio and NG feeding.
If adjustment of medications not sufficient to see improvement need to consider high dose steroid and plasma exchange therapy.
18. Drugs to avoid Polymyxin group of antibiotics
Aminoglycosides
B blockers
Procainamide, lignocaine
Suxamethonium
19. Associated disorders Thyroid abnormality
Rheumatoid disease
Scleroderma
Psoriasis
Polymyositis
SLE
Pernicious anaemia
20. anaesthesia Pre op optimisation
Airway assessment if RA
Avoid premedication
Avoid depolarising mr
Reduce dose of non-depolarisers if any used at all, monitoring at all times
Continue steroid and give additional on day of surgery
Post op hdu-up to 33% require ventilation predicted by long pre-op hx MG, high anticholinesterase requirements, VC <2.9l.
21. Guillain Barre Syndrome Acute demyelinating polyneuropathy
Commonest cause of rapid-onset flaccid paralysis since polio decline
Occurs as an autoimmune response following a GI or respiratory infection
Potentially severely debilitating disorder affecting 1-3 per 100,000
10% die from associated complications
A further 10% suffer from long term neurological sequelae and physical dependence
22. Guillain, Barre and Strohl first described a disease affecting French soldiers ( motor weakness, areflexia and CSF abnormalities) in 1916
Descriptions date back to 1859 when Laundry described ascending paralysis
23. Despite well recognized syndrome and potentially fatal
Often misdiagnosed and subtle signs of decompensation missed
24. Aetiology All ages affected with bimodal distribution towards young adults and the elderly
Slight male preponderance
Children less severely affected
Most commonly occurs within a month of GI or resp upset.
Commonest organism is campylobacter
Others inc EBV, CMV, complication of HIV
25. Have been reports of association with vaccines, surgery, epidurals, bone marrow and organ transplantation, SLE, lymphoma, sarcoidosis
Pregnancy and OCP confer some protection
26. Pathogenesis Immunologically mediated nerve injury
Inflammatory cell infiltrates are seen in association with the demyelination, which is regarded as the primary pathological process
Precise mechanism of sensitisation not known
Peripheral nerves show infiltration of the endoneurium by mononuclear cells in a perivenular distribution
27. Distributed throughout the nerve length but focused at nerve roots, spinal nerves and major plexuses
Macrophages actively strip myelin from bodies of schwann cells and axons
Underlying immune response is complex
Effectiveness of plasma exchange and IgG is thought to be blocking of demyelinating antibodies
28. Clinical presentation Several distinct clinical pictures described
Acute inflammatory demyelinating polyradiculopathy (AIDP)
Acute motor axonal neuropathy (AMAN)
Acute motor sensory axonal neuropathy (AMSAN)
Miller-Fisher syndrome ( ataxia, areflexia and opthalmoplegia which may be accompanied by limb weakness, ptosis and facial and bulbar palsy
29. Classical picture is that of ascending limb weakness with areflexia, although a purely sensory variant has been well documented
Features of GBS include
Progressive motor weakness, usually ascending from the legs
Areflexia
Facial palsy and bulbar weakness
Opthalmoplegia
Sensory symptoms
30. Severe pain esp girdle
Resp muscle weakness
Autonomic dysfunction( over or underactivity of the SNS or PSNS)
31. Features required for diagnosisdefined by national institute of neurological and communicative diseases and strokes Progressive muscle weakness of more than one limb
Areflexia or marked hyporeflexia
CSF cell counts of no more than 50 monocytes or 2 polymorphonuclear leucocytes
Features highly suggestive
Features required to rule out other diagnosis
32. Differential diagnosis Rapidly progressive space occupying lesion eg epidural abscess
Critical illness polyneuropathy, associated with recovery from multiorgan failure, steroids and muscle relaxants
EMG shows pure axonal degeneration patterns compared to demyelination seen in GBS
CSF protein level normal in CIP
33. Monitoring Cardiac
Blood pressure
Vital capacity measured three times a day
Bulbar function monitored to prevent aspiration
34. Investigations In over 90% patients CSF protein is raised ( >0.4g/l) within a week of onset of symptoms
Level does not correlate with clinical findings
Nerve conduction studies demonstrate reduced conduction velocity
Liver and renal function may be impaired
Antiganglioside antibody should be searched for
35. SIADH may occur in association with GBS
Stool cultures for campylobacter
Ecg’s for QT, T and ST abnormalities
Head CT to exclude raised ICP and other pathology prior to LP
36. Treatment Major challenge
Outcome excellent if complications treated or avoided
Prevented by meticulous attention to detail
37. Specific treatment-disease modifying modalities Plasma exchange
Immunoglobin
Both should be used when patient non-ambulatory or resp decompensation occurs
Both have been examined in RCT and no difference in efficacy demonstrated between them
38. Plasma exchange 2 RCT showed reduction in ventilation and reduced time to motor recovery
Mortality was not altered
Most effective within 7 days of onset
3-5 exchanges of 1-2 plasma volumes each over 1-2 weeks
Ffp more complications than albumin
CI include CVS instability, sepsis and haemostatic problems
Side effects are hypotension, hypocalcaemia,coagulation abnormalities and sepsis
39. IV Immunoglobin 0.4mg/kg daily for 5-6 days
Easier administration
Fewer side effects
Commence tx within 2 weeks of onset of symptoms
CI include IgA deficiency(anaphylaxis)
Renal function may deteriorate
Severe congestive cardiac failure major contraindication
RCT has suggested as effective as plasma exchange
40. Steroids No place in the treatment of GBS
RCT have shown no advantage
41. CSF filtration Few case reports
When plasmapheresis and IgG have failed
Logistics difficult!
42. Supportive care Respiratory,
25% require ventilated
Physio and VC monitoring in the spont breathing. If less than 15ml/kg or rising pCO2 ventilation likely
Monitoring of bulbar function for prevention of aspiration
Non-invasive ventilation often not useful as does not eliminate the problem of not being able to clear secretions due to poor cough
Early tracheostomy should be considered
43. Supportive care Cardiovascular
Full invasive monitoring
Care with induction of anaesthesia as leads to hypotension and arrhythmias
Care with suxamethonium may lead to arrhythmias
Instability may be worsened by other drugs
Autonomic instability common
44. Supportive care Nutrition, fluid and electrolytes
Paralytic ileus common
Tpn may be required
Energy and fluid requirements are reduced in these patients
Physiotherapy
DVT prophylaxis
Sepsis survellience
Psychological care
analgesia
45. Prognosis Death in up to 25% of those who require ICU has been reported often from autonomic abnormalities
Approx 16% patients suffer permanent disability
Those who require ventilation, improve after more than 3 weeks, not improved within 1 month have greater risk of poorer outcome
Gradual improvement may occur over 18months -2years
Recurrence n 2-5% cases